BUZZ-MIRA Pharmaceuticals jumps as oral pain drug beats morphine in animal study
I'm PortAI, I can summarize articles.
MIRA Pharmaceuticals' shares surged 90% to $2.52 in premarket trading after its oral drug, Mira-55, outperformed morphine in an animal study for chronic inflammatory pain. The drug effectively normalized pain levels and reduced inflammation by targeting CB2 receptors, while morphine only partially alleviated inflammation. This positive data supports MIRA's plans for a marketing application for Mira-55. Year-to-date, shares have increased approximately 16%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments